Agent |
Lumbar puncture (with or without catheter introduction) |
Removal of epidural or spinal catheter in patients treated with anticoagulantsb |
Starting antithrombotic prophylaxis after spinal or epidural anesthesia |
ASA |
No restrictions |
No restrictions |
No restrictions |
Clopidogrel |
≥7 days from drug discontinuation (min 5) |
– |
After catheter removal |
Prasugrel |
≥10 days from drug discontinuation (min 7) |
≥10 days from drug discontinuation |
After catheter removal |
Ticagrelor |
≥5 days from drug discontinuation (min 3) |
– |
After catheter removal |
VKAc |
4 days from drug discontinuation + normal INR |
When INR <1.5 |
After catheter removal |
UFH IV |
4 h after discontinuation of IV infusion and aPTT normalization |
4 h after discontinuation of infusion and aPTT normalization |
– >2 h after catheter removal – Defer by 12 h in case of bloody puncture (applies to intraoperative use of IV UFH) |
UFH SC |
4 h after SC injection of prophylactic dose |
4 h after SC injection of prophylactic dose |
1 h after catheter removal |
LMWH SC |
– 10-12 h after standard prophylactic dose – 24 h after last therapeutic dose and after normalization of anti-Xa activity |
– 10-12 h after last dose and 4 h before next dose – 24 h after last dose (with doses administered every 24 h) |
– 2-4 h after catheter removal – Defer by 24 h in case of bloody puncture (applies to therapeutic dose) |
Fondaparinux |
– 24-36 h after standard prophylactic dose (2.5 mg SC every 24 h) – 48-72 h after standard therapeutic dose (7.5 mg SC every 24 h) |
36-42 h after last dose (no data available on safety of fondaparinux in patients with indwelling spinal or epidural catheters; other anticoagulants should be used) |
– 6-12 h after catheter removal in patients receiving prophylactic doses (2.5 mg SC every 24 h) – 12-24 h after catheter removal in patients receiving therapeutic doses (7.5 mg SC every 24 h) or patients at high bleeding risk |
Factor Xa inhibitor (oral)d |
Hold day of procedure and 2 days prior (>48 h after last dose) |
Hold day of procedure and 2 days prior (>48 h after last dose) |
6-12 h after catheter removal in patients starting prophylactic dosesf ≥24 h after removal of catheter in patients resuming therapeutic dosesg |
Direct thrombin inhibitor (oral)e |
Hold day of procedure and 2 days prior (>48 h after last dose; hold 4 days if CrCl <50 mL/min) |
Hold day of procedure and 2 days prior (>48 h after last dose; hold 4 days if CrCl <50 mL/min) |
6-12 h after catheter removal in patients starting prophylactic dosesh ≥24 h after catheter removal in patients resuming therapeutic dosesi |
a No high-quality data is available for oral direct factor Xa inhibitors or thrombin inhibitors. b Applies to patients with normal renal function. c Acenocoumarol and warfarin. d Apixaban, edoxaban, and rivaroxaban. e Dabigatran. f Apixaban 2.5 mg bid, edoxaban 30 mg once daily, or rivaroxaban 10 mg once daily. g Apixaban 5 mg bid, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily. h Dabigatran 150-220 mg once daily. i Dabigatran 110-150 mg bid. | |||
aPTT, activated partial thromboplastin time; ASA, acetylsalicylic acid; bid, 2 times a day; CrCl, creatinine clearance; INR, international normalized ratio; IV, intravenous; LMWH, low-molecular-weight heparin; SC, subcutaneous; UFH, unfractionated heparin; VKA, vitamin K antagonist. |